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exosites in Hypervariable Loops 
of ADAMtS Spacer Domains 
control Substrate Recognition and 
proteolysis
Salvatore Santamaria1, Kazuhiro Yamamoto2, Adrienn teraz-orosz1, christopher Koch3,4, 
Suneel S. Apte3, Rens de Groot  1, David A. Lane1 & Josefin Ahnström1
ADAMTS (A Disintegrin-like and Metalloproteinase domain with Thrombospondin type 1 Motif)-
1, -4 and -5 share the abilities to cleave large aggregating proteoglycans including versican and 
aggrecan. these activities are highly relevant to cardiovascular disease and osteoarthritis and during 
development. Here, using purified recombinant ADAMTS-1, -4 and -5, we quantify, compare, and define 
the molecular basis of their versicanase activity. A novel sandwich-eLiSA detecting the major versican 
cleavage fragment was used to determine, for the first time, kinetic constants for versican proteolysis. 
ADAMTS-5 (kcat/Km 35 × 105 M−1 s−1) is a more potent (~18-fold) versicanase than ADAMTS-4 (kcat/Km 
1.86 × 105 M−1 sec−1), whereas ADAMTS-1 versicanase activity is comparatively low. Deletion of the 
spacer domain reduced versicanase activity of ADAMTS-5 19-fold and that of ADAMTS-4 167-fold. 
Co-deletion of the ADAMTS-5 cysteine-rich domain further reduced versicanase activity to a total 153-
fold reduction. Substitution of two hypervariable loops in the spacer domain of ADAMTS-5 (residues 
739–744 and 837–844) and ADAMTS-4 (residues 717–724 and 788–795) with those of ADAMTS-13, 
which does not cleave proteoglycans, caused spacer-dependent reductions in versicanase activities. 
our results demonstrate that these loops contain exosites critical for interaction with and processing 
of versican. The hypervariable loops of ADAMTS-5 are shown to be important also for its aggrecanase 
activity. Together with previous work on ADAMTS-13 our results suggest that the spacer domain 
hypervariable loops may exercise significant control of ADAMTS proteolytic activity as a general 
principle. Identification of specific exosites also provides targets for selective inhibitors.
The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motif) family comprises 19 secreted 
zinc endopeptidases in humans. The family members share a common domain structure which comprises a large 
prodomain, responsible for maintaining the enzyme in an inactive form, a metalloproteinase catalytic domain 
(Mp), a disintegrin domain (Dis), a thrombospondin-1-like motif (Ts), a cysteine-rich domain (CysR), a spacer 
domain (Sp) and a variable number of additional C-terminal ancillary domains. A subgroup of ADAMTS pro-
teases, comprising ADAMTS-1, -4, -5, -8, -9, -15, -20, are collectively referred to as proteoglycanases due to their 
ability to cleave large aggregating proteoglycans (such as versican, aggrecan, brevican and neurocan)1. These 
proteoglycans have a similar structure, comprising a globular N-terminal domain (G1), involved in binding to 
hyaluronan, a central glycosaminoglycan (GAG) domain containing attachment sites for GAGs, and a globular 
C-terminal domain (G3). They generate high osmotic pressure due to the negative charges on their GAGs and 
therefore are essential for the biomechanical properties of the extracellular matrix and tissue swelling. As a con-
sequence, their cleavage and turnover by ADAMTS proteoglycanases has dramatic regulatory consequences for 
both cells and tissues. For example, genetic deletion of ADAMTS-5 in mice significantly reduced cleavage of 
aggrecan, the major proteoglycan in articular cartilage, and elicited protection from post-surgical osteoarthritis 
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(OA) and inflammatory-induced arthritis2,3. These findings stimulated the development of ADAMTS-5 inhibi-
tors for treatment of OA4,5. Another important substrate is versican, which is broadly expressed and is essential 
for normal embryogenesis6, via a role in numerous cellular processes7. Four versican isoforms (V0-V3) arise 
from alternative splicing of two large exons encoding chondroitin-sulfate (Cs) attachment sites, termed αGAG 
and βGAG7. ADAMTS-catalysed proteolysis of the versican V1 isoform, a major component of non-neural tis-
sues, occurs at the Glu441↓442Ala bond within the βGAG region (Fig. 1a), generating an N-terminal fragment 
named versikine8,9. This versicanase activity is associated with ovulation and parturition and major embryological 
processes such as craniofacial and cardiac morphogenesis, neural crest cell migration and limb development10. 
Moreover, ADAMTS-1, -4 and -5 are implicated in the pathogenesis of cardiovascular diseases11. ADAMTS-5 
regulates lipoprotein retention in murine models of atherosclerosis via versican turnover12. Genetic deletion of 
ADAMTS-4 in apolipoprotein E (apoE) knock out mice reduced plaque vulnerability and plaque burden13, and 
versican proteolysis by ADAMTS-1 is associated with smooth muscle cell migration14. Despite the importance of 
these findings, the relative activities of these proteases and their structural basis in proteoglycan recognition and 
proteolysis remain poorly understood.
Figure 1. Comparison of the versicanase activity of ADAMTS-1, -4 and -5. (a) Domain structures of V1, V1-
5GAG and versikine (VSK), the N-terminal cleavage product resulting from ADAMTS-mediated cleavage 
at Glu441↓442Ala. (b) Coomassie staining of purified V1 and V1-5GAG following chondroitinase ABC 
digestion. Full-length gels are shown in Supplementary Fig. 1. (c,d) Versicanase activity of ADAMTS-1, -4 
and -5. V1 (c) and V1-5GAG (d) (each 100 nM) were incubated with full length ADAMTS-1, -4 and -5 for 
2 h at 37 °C. Samples were deglycosylated, subjected to SDS-PAGE and blotted either with polyclonal anti-Vc 
or anti-DPEAAE neoepitope antibodies. Enzyme concentrations were chosen with consideration for the 
relative difference in versicanase activity. IB: immunoblot. Full-length anti-DPEAAE blots are presented in 
Supplementary Fig. 1.
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The ADAMTS-5 Sp domain is known to be strictly required for its aggrecanase activity15. Notably, 
ADAMTS-13, a distantly related protease that cleaves the haemostatic protein von Willebrand Factor (VWF), also 
requires the Sp for substrate binding16. However, specific exosites involved in substrate recognition and proteoly-
sis have not been identified for ADAMTS-5, nor for any other proteoglycanase. So far studies of proteoglycanase 
activity have been limited to semi-quantitative western blots. Furthermore, low expression levels of the recombi-
nant proteases have inhibited detailed investigations of their enzymatic and binding properties15,17.
Here, we use versican as a prototype proteoglycan substrate to define the molecular basis of proteogly-
canase activity of ADAMTS-1, -4 and -5. Its recombinant expression9 and availability of a well-characterized 
neoepitope antibody, anti-DPEAAE, against a major ADAMTS cleavage site8 provide an opportunity to study 
proteoglycanase activity in a quantitative manner. Using a newly developed versicanase activity assay and insights 
gleaned from prior work on ADAMTS-13, we directed this analysis to highly variable loops in their Sp domains. 
We demonstrate here that these loops contain exosites that are important for proteoglycan recognition and 
proteolysis.
Results
Versicanase activity of ADAMTS-1, -4 and -5. Purified recombinant versican V1 and its variant trun-
cated after Phe694 in the βGAG region9, V1-5GAG, provided homogenous preparations of proteoglycan for 
quantitative measurements (Fig. 1b). Importantly, V1-5GAG contains the Glu441↓442Ala cleavage site (Fig. 1a).
To qualitatively compare the versicanase activities of ADAMTS-1, -4 and -5, we used initially SDS-PAGE 
followed by western blotting. Purified V1 and V1-5GAG were incubated with purified full-length ADAMTS-1, 
-4 and -5. The reactions were stopped with EDTA and the digestion products were deglycosylated and subjected 
to SDS-PAGE and western blotting using either an antibody against the sequence 432-VPKDPEAAEARRG-445 
(anti-Vc), which spans the Glu441↓442Ala cleavage site and recognizes both full-length V1/V1-5GAG and 
versikine9, or anti-DPEAAE, which only detects versikine8 (Fig. 1c,d). As previously observed9, in V1 the anti-Vc 
antibody detected a band at ~150-kDa (similar size of V1-5GAG), suggesting proteolysis at alternative cleavage 
sites within the βGAG region during the expression and purification (Fig. 1c). However, this band was not visible 
in the Coomassie staining (Fig. 1b). The ~150-kDa cleavage band therefore likely represents a minor proportion 
of V1 preparations, only detected due to the high affinity of the anti-Vc antibody.
At the lowest concentration tested (2 nM), ADAMTS-5 completely converted both substrates into versikine 
(the ~75-kDa band). In contrast, cleavage by ADAMTS-4 was incomplete even at 5 nM. Very weak versicanase 
activity was observed for ADAMTS-1, even at concentrations as high as 500 nM.
For precise quantitation and direct comparison of versicanase activities, we developed a sandwich-ELISA 
based on the specific recognition of versikine. V1 and V1-5GAG were digested by versicanases essentially as 
described above. The digested samples were analysed with an ELISA in which the N-terminal versikine fragments 
were captured by anti-DPEAAE neoepitope antibodies and detected with anti-G1 antibodies. As shown in Fig. 2a 
the ELISA specifically detected versikine, but not undigested V1/V1-5GAG. Following complete digestion with 
ADAMTS-5, the two substrates generated very similar binding curves. These results show that the assay could be 
used to determine the kinetic efficiency of proteolysis of both V1 and V1-5GAG by ADAMTS-1, -4 and -5. This 
was initially determined by measuring cleavage over time at single substrate concentrations. Both ADAMTS-4 
and -5 showed very similar specificity constants (kcat/Km) against V1 and V1-5GAG (Table 1), suggesting that the 
latter substrate contains all binding sites necessary for cleavage at Glu441↓442Ala. Full-length ADAMTS-5 was 
approximately 18-fold more potent than full-length ADAMTS-4 against both substrates (kcat/Km ~ 35 × 105 ver-
sus 1.86 × 105 M−1 s−1, Table 1). Due to the very low versicanase activity of ADAMTS-1 (Fig. 1c,d), its specificity 
constants were not determined. As both V1 substrates were cleaved with similar efficiencies, we used V1-5GAG 
to determine the turnover numbers (kcat) and Michaelis-Menten constants (Km) for ADAMTS-4 and -5 by meas-
uring the initial velocity of proteolysis at different concentrations of substrate (Fig. 2b,c). Comparable kcat/Km 
Figure 2. Kinetic constants for the versicanase activity of ADAMTS-4 and -5. (a) Representative ELISA 
standard curves of V1 and V1-5GAG digested with ADAMTS-5 (ATS-5). Following complete digestion of 
either V1 or V1-5GAG (100 nM) with ADAMTS-5, samples were diluted and incubated on a plate coated with 
anti-DPEAAE antibodies as reported in the Method Section. (b,c) Michaelis-Menten curves for proteolysis of 
V1-5GAG by ADAMTS-4 (b) and -5 (c). The enzyme (5.5 nM ADAMTS-4, 0.2 nM ADAMTS-5) was incubated 
with increasing concentrations of substrate. At the indicated time points, an aliquot was taken, proteolysis 
stopped with EDTA and cleavage products measured by ELISA. Data are plotted as turnover number versus 
substrate concentration and are presented as mean ± SEM (n = 3–4).
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values were derived (see also Table 1). ADAMTS-5 achieved its higher versicanase activity by a ~100-fold larger 
kcat which more than compensated for a ~3.5-fold larger Km (Fig. 2b,c).
Structural determinants of ADAMTS-4 and -5 versicanase activity. The contribution of the ancil-
lary domains of ADAMTS-4 and -5 was explored using previously described domain-deletion variants15,17,18 
(Fig. 3a). Initially, we used SDS-PAGE followed by western blotting to visualize the versicanase activity of each 
truncated variant, following a 2 h digestion of V1-5GAG (100 nM) (Fig. 3b). This endpoint experiment indicated 
that removal of the Sp domain (MDTC variant) had a dramatic inhibitory effect on ADAMTS-4 versicanase activ-
ity, as shown by the lack of the anti-DPEAAE reactive cleavage band. For ADAMTS-5, removal of the C-terminal 
TS-1 domain (MDTCS) had no effect on versicanase activity, whereas removal of the Sp domain (MDTC) 
resulted in reduced V1-5GAG proteolysis. Further removal of the CysR domain (MDT) severely affected versi-
canase activity. We then accurately determined the specificity constants of these domain deletion variants in time 
course experiments. Note that Fig. 3c,d show a comparison of versicanase activities using the same enzyme con-
centration for all the variants, whereas the values reported in Table 1 were measured using higher concentrations 
of the variants to induce sufficient cleavage of the substrate, as reported in the Experimental procedures. Deletion 
of the Sp domain decreased ADAMTS-4 versicanase activity by 167-fold (Fig. 3c and Table 1). Deletion of the 
C-terminal TS-1 domain of ADAMTS-5 did not alter versicanase activity, whereas deletion of the Sp domain 
decreased activity by 19-fold (Fig. 3d and Table 1). The magnitude of this decrease was underestimated in the 
western blot shown in Fig. 3b because of the higher substrate and enzyme concentrations used in these experi-
ments as well as the later endpoint (2 h) chosen to stop the reaction (see Experimental procedures). A previously 
described inhibitory antibody directed against the ADAMTS-5 Sp domain, 2B918, also decreased the versicanase 
activity of ADAMTS-5 by ~5-fold (Table 1). Since ADAMTS-5 MDTC still retained versicanase activity, the ini-
tial velocities at increasing V1-5GAG concentrations were measured to evaluate the consequence of removal of 
the Sp domain on the kinetic constants. An increase (>30-fold) in Km was found, reflecting a decrease in affinity 
for the substrate (Fig. 3e). Accordingly, the Sp domain mediates the affinity between ADAMTS-5 and proteogly-
cans. Further deletion of the CysR (MDT) and central TS-1 (MD) domains decreased ADAMTS-5 versicanase 
activities by 153- and 276-fold, respectively, demonstrating that the other ancillary domains, C-terminal to the 
Mp/Dis domains, are essential for versicanase activity.
Identification of hypervariable loops in the ADAMTS-4 and -5 Sp domains bearing essential 
exosites for versicanase activity. The overall fold of the ADAMTS Sp domain was revealed when the 
structure of the ADAMTS-13 Sp domain was resolved19. This showed that the domain consists of ten β-strands 
in a jelly-roll topology. Of the nine connecting loops, three (β1-β2, β9-β10 and β3-β4) compose a single interface, 
which in ADAMTS-13 includes a functional exosite (in the β9-β10 loop) responsible for binding to its phys-
iological substrate, VWF19,20 (Fig. 4). Interestingly, loops β1-β2, β9-β10 and β3-β4 are highly variable among 
the otherwise homologous ADAMTS-4 and ADAMTS-5, as well as ADAMTS-1 and the more distantly-related 
ADAMTS-13 (Fig. 4), suggesting they could potentially be responsible for substrate-specific interactions.
To get insight into any exosites present in the Sp domains of ADAMTS-4 and ADAMTS-5, we modelled their 
structures onto that of ADAMTS-13 (Fig. 5a,b): the derived model of ADAMTS-4 is depicted. We hypothesized 
that loops β1-β2, β9-β10 and/or β3-β4 of ADAMTS-4 and -5 may contain exosites that are important for optimal 
versicanase activity. To investigate this, we substituted individually these loops in ADAMTS-4 and -5, as identi-
fied in the model, with those of ADAMTS-13 (which is unable to cleave proteoglycans)21 (Fig. 5c). This substi-
tution approach was considered less likely to cause major conformational changes to the Sp domain than direct 
deletion of the loop segments. Purified ADAMTS-4/13 and -5/13 chimeras retained the catalytic activities of their 
wild-type enzymes against small quenched-fluorescent substrates. Like wild-type ADAMTS-4 and -5, their con-
centrations could therefore be determined by active-site titration with TIMP-3 (see Experimental procedures). 
Variant Substrate kcat/Kma 105 M−1 s−1
Fold 
reduction
ADAMTS-4
WT V1 1.86 ± 0.37 —
WT V1-5GAG 2.10 ± 0.28 —
MDTC V1-5GAG 0.012 ± 0.005** 167
ADAMTS-5
WT V1 34.6 ± 5.19 —
WT V1-5GAG 35.6 ± 3.80 —
MDTCS V1-5GAG 29.1 ± 3.36 1.2
MDTCS + 2B9 V1-5GAG 7.58 ± 1.50* 4.7
MDTC V1-5GAG 1.86 ± 0.32* 19
MDT V1-5GAG 0.23 ± 0.06*,† 153
MD V1-5GAG 0.13 ± 0.03* 276
Table 1. Kinetic parameters for proteolysis of V1 and V1 5-GAG by ADAMTS -1, -4 and -5 and their deletion 
variants. aValues determined by time course experiments at 50 nM substrate concentration. Results given 
in nanomolar and expressed as mean ± SEM. *p < 0.05, **p < 0.01, compared to wild-type (WT) enzyme. 
†p < 0.05 compared with MDTC (n = 3–9).
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Figure 3. Cleavage of V1-5GAG by ADAMTS-4 and -5 deletion forms. (a) A schematic of the different 
ADAMTS-4 and -5 deletion variants used. (b) V1-5GAG (100 nM) was incubated with different variants of 
ADAMTS-5 and -4 (5 nM) for 2 h at 37 °C. Samples were then deglycosylated, subjected to SDS-PAGE and 
blotted either with the anti-Vc or anti-DPEAAE antibodies. Full-length anti-DPEAAE blot is presented in 
Supplementary Fig. 2.VSK, versikine. IB: immunoblot. (c,d) Time course experiments for cleavage of 50 nM V1-
5GAG by ADAMTS-4 (5.5 nM; C) and -5 (0.2 nM; D) variants. The solid lines represent a nonlinear regression 
fit of the data as described in the Experimental procedures. (e) Michaelis-Menten curves for proteolysis of V1-
5GAG by ADAMTS-5 MDTC. The enzyme (13 nM) was incubated with increasing concentrations of substrate. 
At the indicated time points, an aliquot was taken, stopped with EDTA and cleavage products measured by 
ELISA. Data are plotted as turnover number versus substrate concentration and are presented as mean ± SEM 
(n = 3–6).
Figure 4. Sequence alignment of the Sp domain of human ADAMTS-1, -4, -5 and -13. Uniprot accession 
numbers were Q9UHI8 (ADAMTS-1, aa 725–749), O75173 (ADAMTS-4, aa|686–837), Q9UNA0 
(ADAMTS-5, aa 732–874) and Q76LX8 (ADAMTS-13, aa 556–685). Percentage identities were 23.9, 17.6 
and 14.2%, respectively, compared with ADAMTS-13. Beta strands and β1-β2, β3-β4 and β9-β10 loops are 
indicated. In ADAMTS-13, the vWF-binding exosite in loop β9-β10 is highlighted. Boxes indicate amino acids 
conserved in at least three of the four enzymes and are coloured according physicochemical properties (purple, 
positively charged; yellow, negatively charged; green, apolar; cyan, polar).
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These results suggest that mutations in the Sp domain, similarly to the deletion of the whole domain17, do not 
affect catalytic activity against peptide substrates. This is also in agreement with the inhibitory profile observed 
by anti-Sp antibody 2B9, which specifically inhibits proteoglycanase activity, but not peptidolytic activity18. 
Therefore, using active site-determined concentrations of purified ADAMTS-4/13 and -5/13 chimeras, their abil-
ities to cleave V1-5GAG were compared with their corresponding wild-type and MDTC enzymes using western 
blot (Fig. 5d). The chimeras ADAMTS-4 β3-β4 and β9-β10 and ADAMTS-5 β1-β2 and β9-β10 showed decreased 
versicanase activity, comparable with that of their MDTC variants. Next, we performed time course experiments 
Figure 5. Versicanase activity of ADAMTS-4/13 and -5/13 Sp domain loop chimeras. (a,b) Molecular model 
of the ADAMTS-4 Sp domain highlighting loops β1-β2, β3-β4 and β9-β10. Structures of the ADAMTS-4 MD 
and ADAMTS-13 TCS variants were used as templates. In (a) the spatial localisation of the loops relatively to 
the rest of the molecule is shown, whereas in (b) the loops are highlighted in a cartoon model of the isolated 
Sp domain. (c) Sequences of the β1-β2, β3-β4 and β9-β10 loops in wild-type (WT) ADAMTS-4, -5 and the 
chimeras. (d) V1-5GAG (100 nM) was incubated with different variants of ADAMTS-4 and -5 (5 nM) for 2 h at 
37 °C. Samples were then deglycosylated, subjected to SDS-PAGE and blotted either with either anti-Vc or anti-
DPEAAE antibodies. Full-length anti-DPEAAE blot is presented in Supplementary Fig. 3. VSK, versikine. IB: 
immunoblot. (e,f) Time course experiments for cleavage of 50 nM V1-5GAG by ADAMTS-4 (1 nM; e) and -5 
(0.2 nM; f) Sp domain loop chimeras. Data are presented as mean ± SEM (n = 3–6). The solid lines represent a 
nonlinear regression fit of the data as described in the Experimental procedures.
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using V1-5GAG, quantified the amount of versikine generated using sandwich-ELISA and determined their 
specificity constants (Fig. 5e,f and Table 2). In the case of ADAMTS-4, substituting the β3-β4 and β9-β10 loops 
decreased the versicanase activity by 21- and 13-fold, respectively, whereas substituting the β1-β2 loop had a very 
modest effect (2.2-fold). For ADAMTS-5, substituting the β1-β2 and β9-β10 reduced the versicanase activity by 
43- and 33-fold, respectively, which is within the same magnitude of reduction as the deletion of the Sp domain. 
Substituting the β3-β4 loop only had a modest effect (3.3-fold) upon activity. From our 3D model (Fig. 5a,b), it is 
evident that loops β1-β2 and β9-β10 as well as β9-β10 and β3-β4 are contiguous, suggesting that two different, but 
overlapping, surfaces are involved in the interaction of ADAMTS-4 and -5 with versican.
Shared exosites involved in ADAMTS-5 versicanase and aggrecanase activity. ADAMTS-5 has 
emerged as the major aggrecanase in mouse models of OA2,3, with its aggrecanase activity being 30-fold higher 
than that of ADAMTS-417. To investigate whether the ADAMTS-5 exosites involved versican recognition are also 
important in its aggrecanase activity, we investigated the ability of the chimeric ADAMTS-5/13 loop variants to 
cleave aggrecan at Glu392↓393Ala, a cleavage site shown to be most detrimental to cartilage integrity22 (Fig. 6). 
As previously shown15, removal of the Sp domain (in MDTC) severely reduced aggrecanase activity. Similarly to 
ADAMTS-5 MDTC, ADAMTS-5/13 β1-β2 and β9-β10 chimeric variants showed decreased aggrecan cleavage 
at Glu392↓393Ala compared to wild-type ADAMTS-5 (Fig. 6). These results suggest that the same exosites are 
involved in the recognition of both aggrecan and versican.
Variant kcat/Kma 105 M−1 s−1 Fold reduction
ADAMTS-4
WT 2.10 ± 0.28 —
β1-β2 0.95 ± 0.21* 2.2
β3-β4 0.10 ± 0.01** 21
β9-β10 0.18 ± 0.03** 12
ADAMTS-5
WT 36.0 ± 3.8 —
β1-β2 0.84 ± 0.05** 43
β3-β4 10.6 ± 1.1** 3.3
β9-β10 1.08 ± 0.06** 33
Table 2. Kinetic parameters for proteolysis of V1- 5GAG by ADAMTS -4 and -5 Sp loop chimeras. aValues 
determined by time course experiments at 50 nM substrate concentration. Results given in nanomolar and 
expressed as mean ± SEM. *p < 0.05, **p < 0.01, compared to wild-type (WT) enzyme (n = 3).
Figure 6. Aggrecanase activity of ADAMTS-5 Sp domain loop chimeras. (a) Bovine aggrecan (270 nM) was 
incubated with ADAMTS-5 (1 nM, 2 h) and their Sp loop variants. Samples were deglycosylated, subjected 
to SDS-PAGE and detected using anti-ARGSV neoepitope antibody, which specifically detects cleavage at 
Glu392↓393Ala. (b) Densitometric analysis of aggrecan cleavage (n = 3). The anti-ARGSV-reactive bands were 
quantified and the band in the presence of wild-type (WT) enzyme was set as 100%. The data are presented 
as average ± SEM; n = 3. Statistical analysis was performed using the unpaired Student’s t-test. p < 0.05 was 
considered significant. IB: immunoblot.
8Scientific RepoRtS |         (2019) 9:10914  | https://doi.org/10.1038/s41598-019-47494-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
Proteoglycanase activity has been implicated in a variety of embryological and pathological processes2,3,10,11. The 
identification of ADAMTS-5 as the major aggrecanase in OA2,3 promoted the development of proteoglycanase 
inhibitors to be used as disease-modifying agents. However, due to lack of knowledge of exosites involved in 
specific proteoglycanase/proteoglycan interactions, current inhibitors mainly target the well-conserved catalytic 
domain, resulting in poor selectivity4. To date, the majority of selective ADAMTS inhibitors have been limited to 
monoclonal antibodies5. An understanding of the structural requirements for proteoglycanase activity will make 
these enzymes amenable to selective inhibition through the development of small molecule inhibitors, designed 
to specifically target exosites.
Versican proteolysis by the ADAMTS family has been shown to play a central role in a variety of embryological 
processes and in the growth and compaction of the trabeculae in the ventricular myocardium23,24. We have used 
versican, and the development of a quantitative versicanase assay, to study the molecular mechanisms involved 
in ADAMTS-1, -4 and -5 substrate recognition and proteolysis. These three closely related proteoglycanases have 
all been identified as versicanases and implicated in the pathogenesis of vascular diseases11. Quantification of 
the intrinsic versicanase activity of ADAMTS-1, -4 and -5 could help elucidate their individual contribution 
to versican proteolysis. We have, for the first time, determined specificity constants for versicanase activities of 
ADAMTS-4 and -5 which were in the order of 104–105 M−1 s−1 (Fig. 2b,c and Table 1) and comparable with those 
for cleavage of VWF by ADAMTS-1325–27. In contrast, the activity of ADAMTS-1 against versican was found to be 
low compared to ADAMTS-4 and -5, which is in agreement, and explains, previous observations done in vivo8,12. 
Out of the three ADAMTS family members investigated, we identify ADAMTS-5 as the most efficient versicanase 
with a ~18-fold higher proteolytic activity than ADAMTS-4. This was explained by its ~100-fold higher turno-
ver rate. Using semi-quantitative western blots, ADAMTS-5 has also been reported as a 20–30 fold more potent 
aggrecanase than ADAMTS-417. It appears that out of the three proteoglycanases investigated here, ADAMTS-5 
is consistently the most potent in vitro. Our findings provide a mechanistic rationale behind some phenotypes 
observed in genetic models28. Deletion of the ADAMTS-5 gene led to versican accumulation and decreased lev-
els of versikine during myofibroblast differentiation29 and cardiac valve development30. Furthermore, lack of 
ADAMTS-5 expression lead to increased dilation of the ascending aorta in a model of thoracic aortic aneu-
rysm31, and decreased proteoglycan-mediated lipoprotein retention in apoE knockout mice12.The consensus from 
research performed in various in vivo models is that expression of multiple ADAMTS proteoglycanases is highly 
coordinated in situations such as web regression and palatogenesis, where they act cooperatively10. The different 
efficiencies of these proteases may therefore be of relevance by bringing them together to achieve a required 
threshold of proteolysis required in each specific setting. They are also known to have other substrates28, such 
that some idiosyncrasy is necessary, but preservation of shared characteristics may ensure the necessary pro-
teoglycanase activity. The low versicanase activity observed for ADAMTS-1, which is nonetheless significantly 
associated with versican proteolysis in vivo24,32, may result from the absence of a cofactor, such as fibulin-123,33 in 
the current study.
The versicanase assay allowed us to dissect the contribution of each domain for versicanase proteolysis using 
a series of domain-deletion variants of ADAMTS-4 and -515,17,18 (Fig. 3 and Table 1). Since ADAMTS-5 MD is 
inactive against versican10 and the crystal structure of ADAMTS-5 MD indicates that the Mp and Dis domains 
are structurally integrated34, we focused on the ancillary TCS(T) domains of ADAMTS-4 and -5. We found that 
deletion of the Sp domain reduced the versicanase activity of ADAMTS-4 by ~170-fold, whereas for ADAMTS-5 
both the Sp and CysR domains needed to be deleted to observe a similar reduction. Complementary studies of 
aggrecanase activity using semi-quantitative western blots showed that deletion of the Sp domain in ADAMTS-4 
and -5 reduced activities by 20-fold17 and 4-fold15, respectively. Further deletion of the ADAMTS-5 CysR domain 
reduced its aggrecanase activity by ~200-fold15, suggesting similarities in substrate recognition between aggrecan 
and versican. Our previous research has suggested that the ADAMTS-5 Sp interacts with the aggrecan protein 
core18, whereas its CysR has been shown to be important in contacting GAGs in aggrecan15. In ADAMTS-13, the 
CysR and Sp domains bind to adjacent sequences on VWF26. Similarly to VWF recognition of ADAMTS-13, dual 
domain recognition of substrate occurs also for the ADAMTS-5 interaction with versican and aggrecan.
Since the Sp is essential for the versicanase activity of ADAMTS-4 and plays an important role in that of 
ADAMTS-5, we focused on this domain in our effort to identify exosites. We substituted loop segments (loops 
β1-β2, β9-β10 and β3-β4) of the Sp domain for those in ADAMTS-13, which does not cleave proteoglycans21 
(Fig. 5 and Table 2). The rationale behind this approach was that ADAMTS-13 loop β9-β10 includes a func-
tional exosite responsible for binding to its physiological substrate, VWF19,20. Furthermore, the β1-β2 loop in 
ADAMTS-4 and -5 contains a GAG binding site which could be involved in versican interaction35,36. Sp domain 
loops β3-β4 (aa 717–724) and β9-β10 (aa788–795) in ADAMTS-4 and loops β1-β2 (aa 739–744) and β9-β10 
(837–844) in ADAMTS-5 emerged as important exosites. Intriguingly, we showed that for ADAMTS-5 these 
exosites are important also for aggrecan cleavage at Glu392↓393Ala (Fig. 6), a cleavage site that it is most detri-
mental for cartilage integrity22. The presence of hypervariable sequences in the Sp loops of different ADAMTS 
family members (Fig. 4) suggest that these sequences may be responsible for substrate-specific interactions. 
Furthermore, the identification of exosites involved in substrate binding suggests potential targets for future 
development of ADAMTS-4 and -5 inhibitors.
Methods
expression plasmids and site-directed mutagenesis. Constructs coding for human ADAMTS-4 
and -5 (both full-length and their carboxyl-terminal deletion mutants, Fig. 3a) with a C-terminal FLAG 
(DYKDDDDK) tag in pCEP4 vector were described previously15. ADAMTS-1 was cloned into the 
pCEP4 vector in-frame with a C-terminal FLAG tag using PCR. The PCR was performed using full-
length ADAMTS-1 cDNA as a template and amplified by KOD Hot Start DNA Polymerase (Merck) 
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using forward primer, 5′-ACTGGTACCACCATGCAGCGAGCTGTG-3′ (ADAMTS-1 FW) contain-
ing a KpnI restriction site (underlined) and a Kozak consensus sequence (italic); reverse primer, 5′- 
CTGCCTCGAGCTATTTATCATCATCATCTTTATAATCACTGCATTCTGCCATTGT-3′ (ADAMTS1-REV 
FLAG) containing a XhoI restriction enzyme site (underlined), a stop codon and the FLAG epitope (in Italics). 
PCR was carried out for 35 cycles of denaturation (60 s at 94 °C), annealing (60 s at 55 °C), and extension (3 min 
30 s at 72 °C). The PCR products were digested with KpnI and XhoI (New England Biolabs, 2 h, 37 °C) and ligated 
into pCEP4 vector using T4 DNA Ligase (16 h, 16 °C).
For generation of ADAMTS-4 and -5 mutants, the sequences of ADAMTS-4 and -5 were first cloned into a 
pEGFP-N1 vector using the primers: ADAMTS-4 forward 5′-ACTGGTACCACCATGTCCCAGACAGGCTCG-3′; 
ADAMTS-5 for ward,  5 ′-ACTGGTACCACCATGCTGCTCGGGTGGGCG-3 ′ ;  FLAG reverse, 
5′-CTGCGCGGCCGCCTATTTATCATCATCATCTTTATAATC-3′ (KpnI and NotI restriction sites are under-
lined, stop codon is in bold text and the FLAG epitope (in Italics). PCR was carried out as described above. PCR 
products were digested with KpnI and NotI (2 h, 37 °C) and ligated into pEGFP-N1 using T4 DNA Ligase.
ADAMTS-4/13 and -5/13 Spacer (Sp) domain loop chimeras were generated by reverse PCR using 
ADAMTS-4 and -5 as template and the following set of primers (the inserted ADAMTS-13 sequence is 
underlined): 4KL1 forward, 5′-AGAGCGTACAACAATGTGGTCACTATC-3′; 4KL1 reverse, 5′-GCCAGCTGTGAAG 
GAGCCTGACTGCTT-3′;4KL2 forward, 5′-CTCTTCATCTACTTGGCCCTGA-3′;4KL2 reverse, 5′-AGGCCTGTGCT 
GCCGGACAAGAATGTG-3′;4KL3 forward, 5′-GGCAACCTCAC CCGCCCAGACCTCCGATACAGCTTCTT-
3′;4KL3 reverse, 5′-ATACTCCTCGCCATACCGCACTAGGACTTGCAG-3′;5KL1 forward, 5′-AGAGCGTACACT 
GACGTGGTGAGG-3′;5KL1 reverse, 5′-GCCAGCTGTAAAGGTTCCAACAATCTT-3′;5KL2 forward, 5′-CTCTTC 
GCCTATTTAGCCCTGAAA-3′;5KL2 reverse, 5′-AGGCCTGTGCTGTCGAACTTTTATGTG-3′;5KL3 forward, 
5′-GGCAACCTCACCCGCCCAGACGTCCGTTATAGCTTTTTT-3′;5KL3 reverse, 5′-TACTCCTCG CCATACCG 
TGCAAGAATCTGCAC-3′. The PCR was carried out as above and the PCR products were treated with T4 kinase and 
T4 ligase.
All the constructs were sequenced to confirm that no point mutations were introduced during PCR.
A versican V1 plasmid coding for full-length mature human V1 inserted into pSecTagA after the Igκ secre-
tory leader sequence and the C-terminally-truncated variant V1-5GAG, comprising amino acids 21–694 with 
C-terminal tandem myc/His6 tags were described previously15,37.
cell lines and transfections. Stable cells lines HEK293 EBNA expressing ADAMTS-4 and -5 variants were 
grown in modified Eagle’s medium (MEM) (Sigma) supplemented with 10% fetal calf serum, 2 mM L-glutamine 
(Sigma), 1% non-essential amino acids and penicillin/streptomycin (100 U/mL) (Invitrogen). For ADAMTS-1 
and ADAMTS-4 and -5 Sp domain loop chimeras, transient transfections were carried out in HEK293T cells 
(ATCC) using linear polyethylenimine (PEI). Heparin (from porcine mucosa, Sigma, 200 μg/mL) was added 4 h 
post-transfection.
Protein expression and purification. ADAMTS-1, -4 and -5 were expressed in serum-free MEM con-
taining 200 μg/mL heparin (Sigma) to extract extracellular matrix-bound enzyme, concentrated using a Lab scale 
TFF system (Merck) and purified using anti-FLAG affinity resin (Cat. n.:A2220, Sigma) as previously described17. 
Briefly, after loading the medium, the column was washed with 1 M NaCl to remove heparin38, and the bound 
protein was eluted with 200 μg/ml FLAG peptide (Cat. n.:F3290, Sigma). Proteins were separated by SDS-PAGE 
and analysed by western blot using the following primary antibodies: anti-FLAG M2 mouse monoclonal antibody 
(Cat. n.:1804, Sigma; 1:1000), anti-ADAMTS-4 rabbit polyclonal antibodies directed against the Pro/MP domains 
(aa 52–315) (Cat. n.:185722, Abcam; 1:500), anti-ADAMTS-5 rabbit polyclonal antibodies directed against the 
MP domain (aa 338–368) (Cat. n.:135656, Abcam; 1:500). Purity was assessed by silver-stain. Concentrations 
of active ADAMTS-4 and -5 and their variants were determined under kinetic equilibrium conditions by 
active-site titrations with known concentration of TIMP-3 (Bio-Techne, Cat. n.:973-TM-010, Bio-Techne)39 using 
quenched fluorescent peptides (custom synthesized by Bachem) carboxyfluorescein-A-E↓L-N-G-R-P-I-S-I-A-K
-N,N,N′,N′-tetramethyl-6-carboxyrhodamine [Fam-AE↓LQGRPISIAKTamra, ‘↓’ indicates the cleav-
age site] (for ADAMTS-4) and o-aminobenzoyl-T-E-S-E∼S-R-G-A-I-Y-(N-3-[2,4-dinitrophenyl]-L-
2,3-diamino-propionyl)-K-K-NH2 [Abz-TESE↓SRGAIY-Dpa-KK] for ADAMTS-5 as previously reported40–42. 
Final substrate concentrations were 1 μM and 20 μM for ADAMTS-4 and -5, respectively. Due to lack of suitable 
quenched-fluorescent substrates for ADAMTS-1, total enzyme concentration was measured by optical absorb-
ance at 280 nm using extinction coefficient of 1.373 (E1%, 1 cm) as predicted by the ProtParam Tool (ExPasy).
V1 and V1-5GAG were transiently transfected using PEI in OPTIMEM (Invitrogen) containing 2 mM CaCl2. 
As previously shown9, V1-5GAG, but not V1, was detectable by anti-6x His tag antibody on western blot analyses, 
despite the cloning of the V1-ORF in-frame with the myc-His6 tag (data not shown). This could possibly be due 
to proteolytic loss of the tag in the latter construct. Therefore, V1 was purified using HiTrap DEAE Sepharose 
(GE Healthcare). After sample loading, the column was washed with 10 CV 20 mM Tris-HCl pH 7.4, 250 mM 
NaCl and eluted using a linear gradient of NaCl (250–1000 mM) over 10 column volumes (CV). V1-5GAG was 
purified using a Ni-sepharose column (GE Healthcare) equilibrated with 3 CV TBS (20 mM Tris-HCl pH 7.4, 
150 mM NaCl). Following binding, the column was washed with TBS containing 10 mM imidazole and bound 
proteins were eluted using a linear gradient (10–300 mM) of imidazole. Eluted fractions containing recombinant 
proteins were subjected to SDS-PAGE, pooled, concentrated on Amicon Ultra spin columns (100 kDa cut-off) 
and dialyzed extensively against TBS. Substrates were stored at −80 °C.
evaluation of proteoglycanase activity by western blot. Qualitative analysis of the versicanase 
activity of wild-type ADAMTS-1, -4 and -5 and their domain deletion mutants was carried out by incubating 
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each enzyme (2–5 nM ADAMTS-4 and -5; 5–500 nM ADAMTS-1) with either V1-FL or V1-5GAG (100 nM) in 
TNC-B buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM CaCl2, 0.02% (w/v) NaN3, 0.05% (v/v) Brij® 35) at 
37 °C. Sub-samples were removed and reactions were stopped at different time points (0–24 hours) with ethyl-
enediaminetetraacetic acid (EDTA, 25 mM) in deglycosylation buffer (50 mM sodium acetate, 25 mM Tris HCl 
pH 8.0) containing 0.1 U/mL chondroitinase ABC (AMSbio) for 16 h at 37 °C. Digestions were analysed using 
western blotting under reducing conditions (5% β-mercaptoethanol) on 4–12% Bis-Tris NuPage Gels (Thermo 
Fisher). Versican fragments were detected with either anti-Vc rabbit polyclonal antibody against the βGAG region 
(1 μg/ml)9 or neoepitope anti-DPEEAE rabbit polyclonal antibody (Cat n.: PA1-1748A, Life Technologies).
Aggrecan digestion assays were performed as previously described18. Briefly, aggrecan from bovine articu-
lar cartilage (270 nM) (Cat. n.: A1960 Sigma, numbering according to Uniprot accession number: P13608) was 
incubated with different concentrations of ADAMTS enzymes as reported in the text in TNC-B buffer at 37 °C 
for 2 h. The reaction was stopped with EDTA buffer and aggrecan was incubated with 0.1 U/mL of chondroiti-
nase ABC and keratanase (endo-beta galactosidase, Cat. n.: G6920, Sigma) overnight at 37 °C to remove GAG 
chains. Samples were analysed by western blot under reducing conditions and cleavage products were detected 
using mouse monoclonal BC-3 antibody which detects aggrecan cleavage at the Glu392↓Ala393 bond (Cat n.: 
MA316888, Life Technologies). Immobilon Chemiluminescent HRP substrate (Merck Millipore) was detected 
with a Chemidoc Touch Imaging system (Bio-Rad) and band intensities were measured using Image lab software 
version 5.2.1 (Bio-Rad).
Quantification of versicanase activity by sandwich ELISA. For quantitative analysis of versican 
cleavage products, 96-well Maxisorp plates (Nunc) were coated with 5 μg/mL anti-DPEEAE neoepitope anti-
body (Cat n. PA1-1748A, Life Technologies) in carbonate buffer pH 9.6 (16 h, 4 °C). Washing steps were per-
formed in triplicate with 300 μL phosphate buffered-saline (PBS) containing 0.1% Tween-20 between each 
step. Plates were blocked with 3% bovine serum albumin (BSA)/PBS for 2 h, at room temperature (RT). The 
samples from the digestion experiments were diluted in 3% BSA/PBS and added to the plate (100 μL, 2 h, RT). 
Bound DPEEAE-containing versican fragments were detected using anti-G1 monoclonal antibody (Cat n. 
ab171887, Abcam, 3 μg/mL in 0.5% BSA/PBS) (1.5 h, RT), followed by horseradish peroxidase (HRP)-conjugated 
anti-mouse antibodies (DAKO, 2.4 μg/mL, 1 h, RT). The assay was developed by addition of o-phenylenediamine 
dihydrochloride (OPD, Cat n. 34006, Sigma) for 10 minutes and reactions were stopped with 2 M H2SO4. The 
absorbance was read at 492 nm. For the determination of specificity constants, ADAMTS-5 (final concentra-
tion 1 nM) or -4 (5.5 nM) were incubated with different concentrations of V1-5GAG (0–3200 nM) at 37 °C in 
TNC-B buffer. At different time points (0–14 min), sub-samples were removed and reactions were stopped with 
EDTA. For each dilution, the amount of neoepitope generated was derived from a standard curve (0–1.56 nM) 
of V1-5GAG completely digested with ADAMTS-5. Initial velocities were calculated from the concentration of 
versikine generated as a function of reaction time. These were divided by the enzyme concentration to derive the 
turnover number in s−1. Turnover numbers were then plotted against substrate concentrations and fitted to the 
Michaelis-Menten equation using GraphPad Prism Software to determine kcat and Km values.
For independent quantification of the specificity constants (kcat/Km), digestion reactions were set up exactly 
as in the preceding paragraph, except that 50 nM V1-5GAG was used and data were analysed as previously 
described26. Specificity constants reported in Tables 1 and 2 were measured at the following enzyme concen-
trations: ADAMTS-4 WT: 5.5 nM; 4MDTC: 55 nM; 4β1-β2, 4β3-β4 and 4β9-β10 1 nM; ADAMTS-5 WT and 
MDTC: 0.2 nM; 5MDTC: 2.7 nM; 5MDT: 23 nM; 5MD: 26 nM; 5β1-β2 and 5β9-β10 2.7 nM; 5β3-β4:0.4 nM. All 
assays were performed at least 3 times using different batches of recombinant enzymes.
Statistical analysis. Data are presented as mean ± SEM of at least three independent experiments and were 
analyzed by GraphPad Prism Software. Statistical analysis was performed using by Mann-Whitney test. p < 0.05 
was considered significant.
Molecular modelling of the ADAMTS-4 and ADAMTS-5 Spacer domains. To predict the sec-
ondary and tertiary structure of the ADAMTS-4 and ADAMTS-5 Sp domains they were modelled with the 
Bioinformatics Toolkit of the Max Planck Institute for Developmental Biology, Tübingen, Germany43,44, using the 
structure of ADAMTS-13 (3GHM) as template. Molecular graphics were produced with an open source version 
of Pymol precompiled by Christoph Gohlke (University of California, Irvine).
Data Availability
Reagents and data presented in this study are available from the corresponding authors upon request.
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